Skip to main content

Advertisement

SpringerLink
Log in

High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Objective

High dose (HD) Ara-C combined with a single HD idarubicin dose (IDA) is an efficient and safe salvage regimen for patients with refractory or relapsed acute lymphoblastic leukemia as indicated by phase II studies. No data are available on the pharmacokinetics of IDA after a rapid HD intravenous infusion. An open phase II pharmacokinetic and clinical study was performed to evaluate antileukemic efficacy, IDA pharmacokinetics and to investigate the presence of IDA and its reduced metabolite idarubicinol (IDAol) in cerebrospinal fluid (CSF) of patients treated with HD-IDA.

Patients and methods

Twenty-five patients with refractory or relapsed acute lymphoblastic leukemia received Ara-C 3 g/m2 from days 1–5, idarubicin (HD-IDA) 40 mg/m2 as rapid intravenous (i.v.) infusion on day 3 and subcutaneous G-CSF 5 μg/kg from day 7 until PMN recovery. Pharmacokinetics of IDA was evaluated after HD idarubicin administration in nine of these patients. CSF samples were collected in 15 patients at different times. IDA and IDAol concentrations were quantified by a validated HPLC assay described in detail elsewhere.

Results

Eleven patients (44%, 95% CI: 23–65%) achieved complete remission with median disease free survival for 6 months. After administration of HD-IDA i.v. bolus of 40 mg/m2, plasma level profiles of unchanged drug and IDAol were similar to those previously described after standard dose and measured with the same analytical method. The mean terminal half-life measured for IDA in this group of patients (14.9 h) was not significantly different from the mean value observed after standard dose (13.9 h, P = 0.72). IDAol t 1/2 was also similar after HD-IDA (46.2 h) and standard dose (39.4 h, P = 0.79). Pharmacokinetic data reveal that in our series of patients IDA and IDAol clearances are significantly higher than those observed in patients treated with 12 mg/m2 of IDA but, although the administered dose (mg/m2) of the drug is 3.3 times higher, IDA exposure (measured in terms of AUC) is only 2.3 times and IDAol exposition 2.1 times greater. Furthermore, HD infusion resulted in a ratio between the AUC of parent drug and idarubicinol not different from the value observed with the standard-dose. IDA and IDAol were measurable only in 3 of the 15 cerebrospinal fluid samples collected.

Conclusion

Responses observed in our series are comparable to those reported with other salvage regimens. The IDA exposure lower than expected may explain the safety of the single i.v. administration of 40 mg/m2 of IDA, combined with HD Ara-C, with a degree of myelosuppression equivalent to that reported with this agent administered in standard doses. Our data do not allow us to clearly attribute this behavior to a pharmacokinetic non-linearity since the baseline creatinine clearance, even within normal values, and patient age are significantly different in the two groups. Cerebrospinal fluid penetration was poor, reaching levels not considered as cytotoxic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hoelzer D (1993) Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin North Am 7:139–160

    PubMed  CAS  Google Scholar 

  2. Garcia-Manero G, Thomas DA (2001) Salvage therapy for refractory or relapsed adult acute lymphoblastic leukemia. Hematol Oncol Clin North Am 15:163–205

    Article  PubMed  CAS  Google Scholar 

  3. Weiss MA (1997) Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Leukemia 11:S28–S30

    PubMed  Google Scholar 

  4. Feldaman EJ (2000) High-dose cytarabine-based therapy in adults with acute lymphoblastic leukemia. Leuk Res 24:189–191

    Article  Google Scholar 

  5. Welborn JL (1994) Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am J Hematol 45:341–344

    Article  PubMed  CAS  Google Scholar 

  6. Capizzi RL, Poole M, Cooper MR, Richards F 2nd, Stuart JJ, Jackson DV, White DR, Spurr CL, Hopkins JO, Muss HB (1984) Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase. Blood 63:694–700

    PubMed  CAS  Google Scholar 

  7. Montillo M, Tedeschi A, Centurioni R, Leoni P (1997) Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte coloni-stimulating factor (FLAG-G-CSF). Leuk Lymphoma 25:579–583

    PubMed  CAS  Google Scholar 

  8. Arlin Z, Feldman E, Kempin S, Ahmed T, Mittelman A, Savona S, Ascensao J, Baskind P, Sullivan P, Fuhr HG (1988) Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood 72:433–435

    PubMed  CAS  Google Scholar 

  9. Suki S, Kantarjian H, Gandhi V, Estey E, O’Brien S, Beran M, Rios MB, Plunkett W, Keating M (1993) Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed adult acute lymphocytic leukemia. Cancer 72:2155–2160

    Article  PubMed  CAS  Google Scholar 

  10. Kantarjian HM, Walters RS, Keating MJ, Estey EH, O’Brien S, Schachner J, McCredie KB, Freireich EJ (1990) Mitoxantrone and high dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65:5–8

    Article  PubMed  CAS  Google Scholar 

  11. Hiddeman W, Buchner T, Heil G, Schumacher K, Diedrich H, Maschmeyer G, Ho AD, Planker M, Gerith-Stolzemburg S, Donhuijsen-Ant R (1990) Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytarabine and mitoxantrone (HAM). Leukemia 4:637–640

    Google Scholar 

  12. Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Cook P, Puccio C, Baskind P, Arnold P, RAzis ED (1991) Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 5:712–714

    PubMed  CAS  Google Scholar 

  13. Raanani P, Shpilberg O, Gillis S, Avigdor A, Hardan I, Berkowicz M, Sofer O, Lossos I, Chetrit A, Ben-Yehuda D, Ben-Bassat I (1999) Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine. Leuk Res 23:695–700

    Article  PubMed  CAS  Google Scholar 

  14. Weiss MA, Drullinsky P, Maslak P, Scheinberg D, Golde DW (1998) A phase I trial of a single high dose of idarubicin combined with high dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia 12:865–868

    Article  PubMed  CAS  Google Scholar 

  15. Borchmann P, Hubel K, Schnell R, Engert A (1997) Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 35:80–83

    PubMed  CAS  Google Scholar 

  16. Schleyer E, Kuhn S, Ruhrs H, Unterhalt M, Kaufmann CC, Kem W, Braess J, Straubel G, Hiddeman W (1996) Oral idarubicin pharmacokinetics-correlation of through level with idarubicin area under the curve. Leukemia 10:707–712

    PubMed  CAS  Google Scholar 

  17. Camaggi CM, Strocchi E, Carisi P, Maltoni A, Tononi A, Guaraldi M, Strolin-Benedetti M, Efthymopoulos C, Pannuti F (1992) Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chem Pharmacol 30:307–316

    Article  CAS  Google Scholar 

  18. National Cancer Institute, Division of Cancer Treatment (1998) Common toxicity criteria. National Cancer Institute, Bethesda

    Google Scholar 

  19. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automatic Control 19:716–723

    Article  Google Scholar 

  20. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, Ferrara F, Peta A, Ciolli S, Deplano W, Fabbiano F, Sica S, Di Raimondo F, Cascavilla N, Tabilio A, Leoni P, Invernizzi R, Baccarani M, Rotoli B, Amadori S, Mandelli F (2002) Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL-0288 randomized study. The GIMEMA group. Blood 99:863–871

    Article  PubMed  CAS  Google Scholar 

  21. Cimino G, Elia L, Mancini M, Annino L, Anaclerico B, Fazi P, Vitale A, Specchia G, Di Raimondo F, Recchia A, Cuneo A, Mecucci C, Pane F, Saglio G, Foa R, Mandelli F (2003) Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood 102:2014–2020

    Article  PubMed  CAS  Google Scholar 

  22. Gokbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR, Freund M, Ganser A, Kneba M, Langer W, Lipp T, Ludwig WD, Mashmeyer G, Rieder H, Thiel E, Weiss A, Messerer D (2000) Treatment of adult ALL according to protocols of the German Multicenter Study Group for adult ALL (GMALL). Hematol Oncol Clin North Am 14:1307–1325

    Article  PubMed  CAS  Google Scholar 

  23. Annino L, Fazi P, Specchia G (2001) Mitoxantrone in the induction treatment of adult acute lymphoblastic leukemia: GIMEMA phase II pilot study. Hematologica 86(10 Suppl):20

    Google Scholar 

  24. Giona F, Annino L, Rondelli R, Arcese W, Meloni G, Testi AM, Moleti ML, Amadori S, Resegotti L, Tabilio A, LAdogana S, Fioritoni G, Camera A, Liso V, Leoni P, Mandelli F (1997) Treatment of adults with acute lymphoblastic leukemia in first bone marrow relapse. Results of the ALL R-87 protocol. Br J Haematol 97:896–903

    Article  PubMed  CAS  Google Scholar 

  25. Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE (2002) A single high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 95:581–587

    Article  PubMed  CAS  Google Scholar 

  26. Camera A, Annino L, Chiurazi F, Fazi P, Cascavilla N, Fabbiano F, Marmont F, Di Raimondo F, Recchia A, Vignetti M, Rotoli B, MAndelli F (2004) GIMEMA ALL-Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica 89:145–153

    PubMed  CAS  Google Scholar 

  27. Testi AM, Del Giudice I, Arcese W, Moleti ML, Giona F, Basso G, Biondi A, Conter V, Messina C, Rondelli R, Micozzi A, Micalizzi C, Barisone E, Locatelli F, Dini G, Arico M, Casale F, Comis M, Ladogana S, Lippi A, Mura R, Pinta MF, Santoro N, Valsecchi MG, Masera G, Mandelli F (2002) A single high dose of idarubicin combined with high-dose Ara-C for treatment of first relapse childhood ‘high-risk’ acute lymphoblastic leukemia: a study of the AIEOP group. Br J Haematol 118:741–747

    Article  PubMed  CAS  Google Scholar 

  28. Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O’Brien S, Giles FJ, Gaiewski J, Pierce S, Keating MJ (1999) Primary refractory and relapsed adult acute lymphoblastic leukemia, characteristics, treatment results and prognosis with salvage therapy. Cancer 86:1216–1230

    Article  PubMed  CAS  Google Scholar 

  29. Schimmel KJ, Richel DJ, van den Brimk RB, Guchelaar HJ (2004) Cardiotoxicitty of cytotoxic drugs. Cancer Treat Rev 30:181–191

    Article  PubMed  CAS  Google Scholar 

  30. Karbasian-Esfahani M, Wiernik PH, Novik Y, Paietta E, Dutcher JP (2004) Idarubicin and standard doser cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer 101:1414–1419

    Article  PubMed  Google Scholar 

  31. Bengala C, Danesi R, Guarneri V, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, Innocenti F, Del Tacca M, Mariani M, Conte PF (2003) High-dose consolidation chemotherapy with idarubicin and alkylating agents following induction with gemcitabine–epirubicin–paclitaxel in metastatic breast cancer: a dose finding study. Bone Marrow Transplant 31:275–280

    Article  PubMed  CAS  Google Scholar 

  32. Berg SL, Reid J, Godwin K, Murry DJ, Poplack DG, Balis FM, Ames MM (1999) Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin and their metabolites in the nonhuman primate model. J Pediatr Hematol Oncol 21:26–30

    Article  PubMed  CAS  Google Scholar 

  33. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res 50:6525–6528

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology/Hematology, Division of Hematology, Niguarda Ca’ Granda Hospital, Piazza Ospedale Maggiore, 3, 20162, Milan, Italy

    Alessandra Tedeschi, Marco Montillo, Anna Maria Cafro, Elisabetta Tresoldi, Liliana Intropido, Michele Nichelatti, Laura Marbello, Claudia Baratè & Enrica Morra

  2. Department of Organic Chemistry, University of Bologna, Bologna, Italy

    Elena Strocchi & Carlo Maurizio Camaggi

Authors
  1. Alessandra Tedeschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Montillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena Strocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Maria Cafro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elisabetta Tresoldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liliana Intropido
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michele Nichelatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Laura Marbello
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Claudia Baratè
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Carlo Maurizio Camaggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Enrica Morra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandra Tedeschi.

Additional information

The authors declare that they have no potential conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tedeschi, A., Montillo, M., Strocchi, E. et al. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemother Pharmacol 59, 771–779 (2007). https://doi.org/10.1007/s00280-006-0332-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0332-4

Keywords

Search

Navigation